Suppr超能文献

接种 gp41 预发夹融合中间态肽模拟物可产生针对 HIV-1 分离株的中和抗体。

Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates.

机构信息

Department of Peptide Chemistry, Merck Research Laboratories, Pomezia, 00040 Rome, Italy.

出版信息

Proc Natl Acad Sci U S A. 2010 Jun 8;107(23):10655-60. doi: 10.1073/pnas.1004261107. Epub 2010 May 18.

Abstract

Eliciting a broadly neutralizing polyclonal antibody response against HIV-1 remains a major challenge. One approach to vaccine development is prevention of HIV-1 entry into cells by blocking the fusion of viral and cell membranes. More specifically, our goal is to elicit neutralizing antibodies that target a transient viral entry intermediate (the prehairpin intermediate) formed by the HIV-1 gp41 protein. Because this intermediate is transient, a stable mimetic is required to elicit an immune response. Previously, a series of engineered peptides was used to select a mAb (denoted D5) that binds to the surface of the gp41 prehairpin intermediate, as demonstrated by x-ray crystallographic studies. D5 inhibits the replication of HIV-1 clinical isolates, providing proof-of-principle for this vaccine approach. Here, we describe a series of peptide mimetics of the gp41 prehairpin intermediate designed to permit a systematic analysis of the immune response generated in animals. To improve the chances of detecting weak neutralizing polyclonal responses, two strategies were employed in the initial screening: use of a neutralization-hypersensitive virus and concentration of the IgG fraction from immunized animal sera. This allowed incremental improvements through iterative cycles of design, which led to vaccine candidates capable of generating a polyclonal antibody response, detectable in unfractionated sera, that neutralize tier 1 HIV-1 and simian HIV primary isolates in vitro. Our findings serve as a starting point for the design of more potent immunogens to elicit a broadly neutralizing response against the gp41 prehairpin intermediate.

摘要

激发针对 HIV-1 的广泛中和多克隆抗体反应仍然是一个主要挑战。疫苗开发的一种方法是通过阻断病毒和细胞膜的融合来阻止 HIV-1 进入细胞。更具体地说,我们的目标是引发针对 HIV-1 gp41 蛋白形成的瞬时病毒进入中间物(发夹前中间物)的中和抗体。由于这种中间物是瞬时的,因此需要稳定的模拟物来引发免疫反应。以前,使用一系列工程肽来选择与 gp41 发夹前中间物表面结合的 mAb(表示为 D5),这已通过 X 射线晶体学研究证明。D5 抑制 HIV-1 临床分离物的复制,为这种疫苗方法提供了原理证明。在这里,我们描述了一系列 gp41 发夹前中间物的肽模拟物,旨在对动物中产生的免疫反应进行系统分析。为了提高检测弱中和多克隆反应的机会,在初始筛选中采用了两种策略:使用中和敏感病毒和浓缩免疫动物血清中的 IgG 部分。这通过设计的迭代循环允许逐步改进,从而产生能够在未分级血清中检测到的多克隆抗体反应的候选疫苗,该反应可中和体外的 HIV-1 第 1 层和猿猴 HIV 原始分离物。我们的发现为设计更有效的免疫原以引发针对 gp41 发夹前中间物的广泛中和反应提供了起点。

相似文献

1
Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates.
Proc Natl Acad Sci U S A. 2010 Jun 8;107(23):10655-60. doi: 10.1073/pnas.1004261107. Epub 2010 May 18.
2
A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1.
J Biol Chem. 2014 Oct 24;289(43):29912-26. doi: 10.1074/jbc.M114.569566. Epub 2014 Aug 26.
10
Stabilized trimeric peptide immunogens of the complete HIV-1 gp41 N-heptad repeat and their use as HIV-1 vaccine candidates.
Proc Natl Acad Sci U S A. 2024 May 28;121(22):e2317230121. doi: 10.1073/pnas.2317230121. Epub 2024 May 20.

引用本文的文献

1
Utilizing Machine Learning to Improve Neutralization Potency of an HIV-1 Antibody Targeting the gp41 N-Heptad Repeat.
ACS Chem Biol. 2025 Jul 18;20(7):1470-1480. doi: 10.1021/acschembio.5c00035. Epub 2025 Jun 20.
3
Stabilized trimeric peptide immunogens of the complete HIV-1 gp41 N-heptad repeat and their use as HIV-1 vaccine candidates.
Proc Natl Acad Sci U S A. 2024 May 28;121(22):e2317230121. doi: 10.1073/pnas.2317230121. Epub 2024 May 20.
4
Bringing immunofocusing into focus.
NPJ Vaccines. 2024 Jan 9;9(1):11. doi: 10.1038/s41541-023-00792-x.
7
A variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein.
Cell Res. 2022 Dec;32(12):1068-1085. doi: 10.1038/s41422-022-00746-3. Epub 2022 Nov 10.
8
Novel chimeric proteins mimicking SARS-CoV-2 spike epitopes with broad inhibitory activity.
Int J Biol Macromol. 2022 Dec 1;222(Pt B):2467-2478. doi: 10.1016/j.ijbiomac.2022.10.031. Epub 2022 Oct 8.

本文引用的文献

1
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.
N Engl J Med. 2009 Dec 3;361(23):2209-20. doi: 10.1056/NEJMoa0908492. Epub 2009 Oct 20.
2
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.
Science. 2009 Oct 9;326(5950):285-9. doi: 10.1126/science.1178746. Epub 2009 Sep 3.
3
Peptides in the treatment of AIDS.
Curr Opin Struct Biol. 2009 Aug;19(4):473-82. doi: 10.1016/j.sbi.2009.07.003. Epub 2009 Jul 23.
4
Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques.
Nat Med. 2009 Aug;15(8):951-4. doi: 10.1038/nm.1974. Epub 2009 Jun 7.
7
Challenges in the development of an HIV-1 vaccine.
Nature. 2008 Oct 2;455(7213):613-9. doi: 10.1038/nature07352.
10
The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus.
Nat Rev Microbiol. 2008 Feb;6(2):143-55. doi: 10.1038/nrmicro1819.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验